Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ6536MR)

This product GTTS-WQ6536MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_001243280.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	214
UniProt ID	Q13740

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6536MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6282MR	IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CS-1001
GTTS-WQ1620MR	IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	ACE-910
GTTS-WQ7566MR	IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	GC33
GTTS-WQ7851MR	IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	GSK-1223249
GTTS-WQ13488MR	IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	PRTX-100
GTTS-WQ2383MR	IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	AMG 102
GTTS-WQ14999MR	IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	SJ25C1 scFv-28Z CAR
GTTS-WQ1285MR	IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	ABT-555

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST